New Cardiovascular Devices Will Improve Treatments for Vascular
Disease Including Stroke, According to a New Report from MedDevice
Concepts
ANDOVER, Mass. (Business Wire EON/PRWEB ) May 28, 2007 --
Cardiovascular ultrasound therapy sales will approach $400M in five
years, according to a new report from MedDevice Concepts. The number of
procedures will grow at a compound rate of 46% per year. By 2011,
177,000 patients will be treated with the new devices, few of which are
commercially available today.
Sonolysis therapies will contribute most of that growth. New devices and
microbubble agents are aimed at vascular disease, including stroke and
peripheral vascular occlusions. Blood clots block blood flow and cause
damage throughout the body in the heart, legs and brain. Ultrasound
devices enable dissolution of blood clots by directing ultrasound energy
alone, combining ultrasound with a thrombolytic drug, or by triple
therapy of ultrasound, drug and microbubble agent to accelerate the
therapeutic effect. By 2010, “designer bubbles”
are expected to be used for treatment of acute ischemic stroke patients
- more than 85% of the 700,000 Americans who suffer from “brain
attack” each year.
A new approach for vascular closure is also expected to be available by
the end of the decade. “The ultrasound device
from Therus retains the distinction of the most original, and in my
opinion, revolutionary concept in vascular closure. It falls into the
distinctive category of noninvasive, active approximation, with no
foreign body left behind.” said Dr Zoltan
Turi, Director of the Cooper Vascular Center at the Robert Wood Johnson
Medical School (Endovascular Today, Feb 2007).
Another new device is an ultrasonic tourniquet that will help save lives
on the battlefield. The U.S. Department of Defense is investing $51
million to develop a cuff-like device that will non-invasively clot
blood vessels and stop internal bleeding - the leading preventable cause
of death of soldiers in action.
“Since 2003, $240 Million of new venture
capital and grants have been invested in cardiovascular therapeutic
ultrasound device startups,” says Al Kyle,
MedDevice President. “It is very likely that
those investments will begin to pay off in the next five years.”
These market developments are the focus of “Emerging
Markets for Cardiovascular Ultrasound Therapy," a new report from
MedDevice Concepts. The report estimates market size and forecasts
revenue for eight companies, based on technology, clinical and
regulatory milestones and benchmarks of comparable device companies.
See the original story at: http://eon.businesswire.com/releases/ultrasound/vascular/prweb529341.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RmFsdS1Ib3JyLVBpZ2ctU2luZy1UaGlyLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
